Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10112103 | 1.00 | ADAM17 (0.43) | ADAM17TNF | |
| SCHEMBL12878375 | 0.87 | ADAM17 (0.44) | ADAM17TNF | |
| SCHEMBL10112007 | 0.87 | ADAM17 (0.43) | ADAM17TNF | |
| SCHEMBL10112111 | 0.85 | ADAM17 (0.44) | ADAM17TNF | |
| SCHEMBL6008403 | 0.84 | ADAM17 (0.42) | ADAM17TNF | |
| SCHEMBL13201492 | 0.84 | DRD2 (0.41) | ADAM17TNF | |
| SCHEMBL13895587 | 0.82 | ADAM17 (0.34) | ADAM17TNF | |
| SCHEMBL10263491 | 0.82 | ADAM17 (0.41) | ADAM17TNF | |
| SCHEMBL10263860 | 0.81 | ADAM17 (0.42) | ADAM17TNF | |
| SCHEMBL5955645 | 0.81 | ADAM17 (0.43) | ADAM17TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569336-B2 | Compounds for the treatment of inflammatory disorders | TONG LING (US) | 2013-10-29 | — | — | US | disclosed |
| US-8541572-B2 | Compounds for the treatment of inflammatory disorders | MERCK SHARP & DOHME CORP. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8450355-B2 | Compounds for the treatment of inflammatory diseases | MERCK SHARP & DOHME CORP. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20120015926-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TONG LING (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120010181-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | MERCK SHARP & DOHME CORP. | 2012-01-12 | — | — | US | disclosed |
| US-20110288077-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISEASES | SCHERING CORPORATION (US) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288077-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISEASES | TNF, ADAMTS13, MMP11 | ADAM17 13/4885TNF 1/4885 |
| US-20120015926-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TNF, ADAMTS1, ADAMTS7 | ADAM17 8/4885TNF 1/4885 |
| US-20120010181-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TNF, ADAMTS1, ADAMTS7 | ADAM17 7/4885TNF 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.